Blueprint Medicines Corp是一家全球精准治疗公司,正在为癌症和血液病患者发明药物。该公司向美国和欧洲的患者提供其已获批准的药物,包括AYVAKIT/AYVAKYT (avapritinib)和GAVRETO(pralsetinib),并在全球范围内推进系统性肥大症(SM)、肺癌、乳腺癌和其他基因组癌症以及癌症免疫疗法的多个项目。其管线还包括Elenestinib(BLU-263)(KIT)、AYVAKIT(avapritinib)(KIT)、野生型KIT研究项目、GAVRETO(pralsetinib)(RET),BLU-945(EGFR),BLU-525(EGFR),BLU-451(EGFR第20号外显子插入),BLU-222(CDK2),AYVAKIT(PDGFRA),GAVRETO(RET),BLU-222(CDK2)和BLU-852(MAP4K1)。该公司正在开发elenestinib(BLU-263),这是一种正在研究的、口服的、强效的和高选择性的KIT抑制剂,用于治疗惰性SM和其他肥大细胞病症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Alexis A. Borisy | 51 | 2011 | Co-Founder & Director |
Jeffrey W. Albers | 52 | 2014 | Chairman |
Kathryn Haviland | 47 | 2016 | President, CEO & Director |
Charles L. Sawyers | 64 | - | Member of Scientific Advisory Board |
Brian J. Druker | 68 | - | Member of Scientific Advisory Board |
William C. Hahn | - | - | Member of Scientific Advisory Board |
Nicholas B. Lydon | 67 | 2011 | Member of Scientific Advisory Board & Independent Director |
Mark A. Goldberg | 70 | 2015 | Independent Director |
George Daniel Demetri | 67 | 2012 | Chair of Scientific Advisory Board |
Lonnel Coats | 59 | 2016 | Independent Director |
Scott W. Lowe | - | - | Member of Scientific Advisory Board |
Habib Joseph Dable | 55 | 2022 | Independent Director |
Daniella Beckman | 45 | 2021 | Independent Director |
Lynn Seely | 65 | 2016 | Lead Independent Director |
John Tsai | 57 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核